West Pharmaceutical Services (NYSE:WST – Get Free Report) and Ambu A/S (OTCMKTS:AMBBY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.
Profitability
This table compares West Pharmaceutical Services and Ambu A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| West Pharmaceutical Services | 16.98% | 20.11% | 14.83% |
| Ambu A/S | 8.18% | 8.49% | 6.75% |
Dividends
West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.2%. Ambu A/S pays an annual dividend of $0.03 per share and has a dividend yield of 0.3%. West Pharmaceutical Services pays out 11.3% of its earnings in the form of a dividend. Ambu A/S pays out 10.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Ambu A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.
Analyst Ratings
This is a breakdown of current ratings and price targets for West Pharmaceutical Services and Ambu A/S, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| West Pharmaceutical Services | 0 | 2 | 12 | 0 | 2.86 |
| Ambu A/S | 0 | 1 | 0 | 0 | 2.00 |
West Pharmaceutical Services presently has a consensus price target of $391.17, suggesting a potential upside of 1.42%. Given West Pharmaceutical Services’ stronger consensus rating and higher possible upside, analysts clearly believe West Pharmaceutical Services is more favorable than Ambu A/S.
Institutional and Insider Ownership
93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Ambu A/S has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Earnings & Valuation
This table compares West Pharmaceutical Services and Ambu A/S”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| West Pharmaceutical Services | $3.07 billion | 8.83 | $493.70 million | $7.81 | 49.39 |
| Ambu A/S | $894.37 million | 3.06 | $90.19 million | $0.30 | 38.80 |
West Pharmaceutical Services has higher revenue and earnings than Ambu A/S. Ambu A/S is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
Summary
West Pharmaceutical Services beats Ambu A/S on 14 of the 16 factors compared between the two stocks.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
About Ambu A/S
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
